Abstracts tagged "Immune regulation"

Abstract Number: 103 • 2019 ACR/ARP Annual Meeting
Serine Arginine-rich Splicing Factor 1 (SRSF1) Is Indispensable for Homeostasis and Function of Regulatory T Cells
Takayuki Katsuyama¹ and Vaishali R. Moulton ¹, ¹Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: Regulatory T cells (Tregs) are pivotal in enforcing immune tolerance to prevent and protect from autoimmunity. Defects in Tregs lead to unchecked immune cell…
Abstract Number: 146 • 2018 ACR/ARHP Annual Meeting
Mesenchymal Stromal Cell Transferred Mitochondria Elicit an Immune Function Reprogramming That Entails T Regulatory Cell Commitment and Clinical Improvement of Graft Vs Host Disease
Angela C. Court¹, Alice Le-Gatt¹, Patricia Luz-Crawford², Monica Kurte², Maria Ignacia Ortuzar¹, Roberto Elizondo², Rafael A. Contreras², Karina Pino-Lagos², Maroun Khoury^3,4 and Fernando E. Figueroa⁴, ¹Cells for Cells, Santiago, Chile, ²Laboratorio de Inmunología Celular y Molecular, Universidad de los Andes, Santiago, Chile, ³Cells for Cells, Santiago de Chile, Chile, ⁴Program for Translational Research in Cell Therapy, Universidad de los Andes, Santiago de Chile, Chile
Background/Purpose: Mesenchymal stromal cells (MSCs) are progenitor cells with suppressive capacities that have fueled ample translation for the treatment of immune mediated diseases including Graft…
Abstract Number: 363 • 2018 ACR/ARHP Annual Meeting
Immune-Related Adverse Events in Cancer Immunotherapy: How Often Do We See Them?
Valeria Scaglioni¹, Marina Scolnik¹, Jose Maria Lastiri², Lorena Lupinacci² and Enrique R Soriano¹, ¹Rheumatology Unit, Internal Medicine Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina, ²Oncology Service. Hospital Italiano Buenos Aires. Argentina, Buenos Aires, Argentina
Background/Purpose: Over the years there has been a huge effort to change the traditional way to treat cancer, that was previously based on chemotherapy and/or…
Abstract Number: 993 • 2018 ACR/ARHP Annual Meeting
Elucidating the Role of the Lymphatic System in the Pathogenesis of Psoriasis and Psoriatic Arthritis
H. den Braanker^1,2, A Otten-Mus³, P Asmawidjaja⁴, N Davelaar⁵, A.A.E.A. de Smet⁶, G.P. Akkersdijk⁶, B. Fioole⁶, J.B. Jaquet⁷, A. Hofman⁸, O.P. Schuitema⁸, Sander W. Tas⁹, R. Mebius¹⁰, Erik Lubberts⁴, M.R. Kok¹¹ and R.J. Bisoendial¹¹, ¹Rheumatology, Maasstad hospital, Rotterdam, Netherlands, ²Immunology and Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ³Rheumatology and Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁵Immunology, Erasmus MC, University Medical Center, Rotterdam, Netherlands, ⁶Vascular surgery, Maasstad hospital, Rotterdam, Netherlands, ⁷Maasstad hospital, Rotterdam, Netherlands, ⁸Plastic Surgery, Maasstad hospital, Rotterdam, Netherlands, ⁹Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ¹⁰Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam, Netherlands, ¹¹Clinical Immunology and Rheumatology, Maasstad hospital, Rotterdam, Netherlands
Background/Purpose: Psoriasis is a common T-cell driven inflammatory skin disorder that is featured by immune cell infiltration, and vasculopathy of both blood and lymphatic vasculature.…
Abstract Number: 1893 • 2018 ACR/ARHP Annual Meeting
Indoleamine-2,3-Dioxygenase in Murine and Human Systemic Lupus Erythematosus
Zev Sthoeger^1,2, Amir Sharabi³, Heidy zinger¹, ilan asher⁴ and edna mozes¹, ¹Department of Immunology, The Weizmann institute of Science, Rehovot, Israel, ²Department of Allergy and Clinical Immunology, Kaplan Medical Center,, Rehovot, Israel, ³Department of Rheumatology, Beth Israel Deaconess Medical Center, Boston, MA, ⁴Department of Allergy and Clinical Immunology, Kaplan Medical Center, Rehovot, Israel
Background/Purpose: Indoleamine-2,3-dioxygenase (IDO) is a tryptophan catabolizing enzyme which plays a role in immune regulation and in the pathogenesis of autoimmune disorders. Increased IDO activity…
Abstract Number: 2832 • 2018 ACR/ARHP Annual Meeting
Multiple Subpopulations of Peripheral Lymphocytes Were Absolutely Decreased in SLE Patients with Infection and Restored By Low-Dose IL-2
Sheng-Xiao Zhang¹, Xiao-Yan Wu², Jing Luo³, Guang-Ying Liu², Chong Gao⁴, Cai-Hong Wang⁵ and Xiao-Feng Li⁵, ¹The Second Hospital of Shanxi Medical University, Taiyuan, China, ²Rheumatology, The Second Hospital of Shanxi Medical University, Taiyuan, China, ³the Second Hospital of Shanxi Medical University, Taiyuan, China, ⁴Department of Pathology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, Cambridge, MA, ⁵The Second Hospital of Shanxi Medical Univerity, Taiyuan, China
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disorder characterized by disturbed cellular and humoral immune responses. Dysregulations of intrinsic or adaptive immune system…
Abstract Number: 1173 • 2017 ACR/ARHP Annual Meeting
Rheumatic Immune Related Adverse Events Due to Programmed Cell Death Protein 1 (PD-1) Inhibition for Cancer: Comprehensive Analysis of a Whole Cancer Cohort
David Liew^1,2,3, Jessica Leung¹, Bonnia Liu¹, Jonathan Cebon^3,4, Albert Frauman^2,3 and Russell Buchanan¹, ¹Department of Rheumatology, Austin Health, Melbourne, Australia, ²Department of Clinical Pharmacology and Therapeutics, Austin Health, Melbourne, Australia, ³Department of Medicine, University of Melbourne, Melbourne, Australia, ⁴Olivia Newton-John Cancer Wellness & Research Centre, Melbourne, Australia
Background/Purpose: Immune checkpoint therapy with programmed cell death protein 1 (PD-1) inhibitors has led to significant survival benefits in the treatment of multiple cancers. This…
Abstract Number: 2419 • 2017 ACR/ARHP Annual Meeting
Immunomodulatory Effects of Bone-Marrow Mesenchymal Stem Cells in Rheumatoid Arthitis: Influence of Disease Activity
Benjamín Fernández-Gutiérrez¹, Jose Ramon Lamas², Yaiza Lopiz³, Cristina Lajas⁴, Lydia A Alcazar⁵ and Luis Rodriguez-Rodriguez⁶, ¹Department of Rheumatology, Hospital Clinico San Carlos, Madrid, Spain, ²Rheumatology, Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ³Cirugía Ortopédica y Traumatología, Hospital Clínico San Carlos, Madrid, Spain, ⁴Rheumatology Department, Hospital Clínical San Carlos, Madrid, Spain, ⁵Rheumatology Department and Heath Research Institute (IdISSC), Hospital Clinico San Carlos, Madrid, Spain, ⁶Department of Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: To analyze the effect of demographic and clinical related characteristics of rheumatoid arthritis (RA) patients in the immunomodulatory effects of mesenchymal stem cells (MSCs).…
Abstract Number: 15L • 2016 ACR/ARHP Annual Meeting
Selective Oral ROCK2 Inhibitor Reduces Clinical Scores in Patients with Psoriasis vulgaris and Normalizes Skin Pathology Via Concurrent Regulation of IL-17 and IL-10 Levels
Alexandra Zanin-Zhorov¹, Jonathan Weiss¹, Alissa Trzeciak¹, Carmen Arencibia¹, Seetharam Polimera¹, Wei Chen¹, Jingya Zhang¹, Melanie Nyuydzefe¹, Judilyn Fuentes-Duculan², Kathleen Bonifacio², Norma Kunjravia², Inna Cueto², Mark Berger¹, James Krueger², Samuel Waksal¹ and John Ryan¹, ¹Kadmon, New York, NY, ²Rockefeller University, New York, NY

Background/Purpose: Rho-associated kinase 2 (ROCK2) was shown to be implicated in regulation of autoimmunity in mice and humans1. Previous findings demonstrated that oral administration of…
Abstract Number: 871 • 2016 ACR/ARHP Annual Meeting
Interleukin 33 Critically Regulates Angiogenesis and Inflammation in Large Vessels Vasculitis
Anne-Claire Desbois¹, Aurélie LEROYER², Marlène Garrido³, Julien Gaudric⁴, Cloé Comarmond⁵, David Klatzman⁶, Philippe Cluzel⁷, Pierre Fouret⁸, Laurent Chiche⁹, Fabien Koskas¹⁰, Gilles Kaplanski¹¹, Patrice Cacoub¹² and David Saadoun¹³, ¹Hôpital Pitié-Salpêtrière, Internal Medicine and Clinical Immunology, Paris, France, ²Faculté de Pharmacie, Marseille, France, ³I3 laboratory, Pitié-Salpétrière, Paris, France, ⁴Department of Vascular surgery GHPS, Paris, France, ⁵DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ⁶UPMC Université Paris 06, UMR 7211, Paris, France, ⁷Cadiovascular Imaging and Interventional Radiology, Pitié-Salpétrière, Paris, France, ⁸Hôpital La Pitié Salpétrière, Paris, France, ⁹Service de Chirurgie Vasculaire, Groupe Hospitalier Pitié-Salpêtrière, Paris, France, ¹⁰Department of Internal Medicine and 2Laboratory I3 « Immunology, Immunopathology, Immunotherapy », UMR CNRS 7211, INSERM U959, Groupe Hospitalier Pitié-Salpetrière, Université Pierre et Marie Curie, Paris 6, Paris, France, Paris, France, ¹¹Aix-Marseille Université - Internal Medicine hopital conception - F-13000 Marseilles, Marseille, France, ¹²Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹³Department of Internal Medicine and clinical Immunology. French National Reference Center for Autoimmune Diseases. DHU I2B (Inflammation, Immunotherapy and Biotherapy), UPMC, Paris VI, Hôpital Pitié Salpétrière, AP-HP, UPMC, Univ Paris 06, Paris, France
Background/Purpose: Large vessels vasculitis (LVV) include Takayasu disease (TD) and Giant Cell Arteritis (GCA). Interleukin 33 (IL-33) is a cytokine which controls immune responses and…
Abstract Number: 1010 • 2016 ACR/ARHP Annual Meeting
Elucidating the Activation Profile of Systemic Sclerosis Macrophages
Michael S. Ball¹, Emilie P. Shipman¹, Mohamed A. Eltanbouly¹, Viktor Martyanov², Kimberly A. Archambault³, Mary A. Carns⁴, Esperanza Arroyo⁴, Kathleen Aren⁴, Monique Hinchcliff⁵, Michael L. Whitfield^2,3 and Patricia A. Pioli¹, ¹Microbiology and Immunology, Geisel School of Medicine at Dartmouth, Hanover, NH, ²Department of Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ³Molecular and Systems Biology, Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL, ⁵Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: Genome-wide gene expression studies implicate macrophages (MØs) as mediators of fibrosis in systemic sclerosis (SSc) and our data indicate that MØs constitute the dominant…
Abstract Number: 1912 • 2016 ACR/ARHP Annual Meeting
A New Avenue of Immune Regulation Conferred By Self-Glycerophospholipids Via Mobilization and Migration of Myeloid-Derived Suppressor Cells
Ramesh Halder¹ and Ram R. Singh^1,2,3, ¹Autoimmunity and Tolerance Laboratory, Department of Medicine/Rheumatology, UCLA, Los Angeles, CA, ²Department of Pathology and Laboratory Medicine, UCLA, Los Angeles, CA, ³Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, CA
Background/Purpose: Lipids function as essential components of biological membranes, as signaling molecules, and as energy storage molecules. Glycerol-based phospholipids, called glycerophospholipids (GPL), are the most…
Abstract Number: 2781 • 2016 ACR/ARHP Annual Meeting
Immunization with ApoB100 Peptide Vaccine Reduces Atherosclerosis Development in a Mouse Model of Systemic Lupus Erythematosus
Ingrid Yao-Mattisson, Maria Wigren, Gunilla Nordin Fredrikson and Jan Nilsson, Lund University, Malmö, Sweden
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by impaired self-tolerance causing damage to multiple organs including the cardiovascular system. Current therapies do…
Abstract Number: 3243 • 2016 ACR/ARHP Annual Meeting
Intestinal Microbial Dysbiosis in SLE Is Linked to Elevated IgA and Induction of Autoimmunity
Doua F. Azzouz¹, Lelise Getu², Celine Anquetil¹, Jill P. Buyon³ and Gregg J. Silverman³, ¹Medicine, NYU School of Medicine, New York, NY, ²Department of Medicine, New York University School of Medicine, New York, NY, ³Medicine, New York University School of Medicine, New York, NY
Background/Purpose: SLE is a complex multifactorial systemic autoimmune disease, which has been attributed to poorly understood interactions between genetic and environmental factors. Recent reports have…
Abstract Number: 206 • 2015 ACR/ARHP Annual Meeting
Activation of Non-Canonical NF-Kappa B Signalling in Dendritic Cells Induces Extrathymic Autoimmune Regulator (AIRE) Expression
Leonie Huitema¹, Boy Helder¹, Ae-Ri Noort², Chrissta Maracle¹, Louis Boon³, Cristina Lebre⁴, Frans G.M. Kroese⁵ and Sander W. Tas⁶, ¹Amsterdam Rheumatology & immunology Center | Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ²Department of Clinical Immunology & Rheumatology and Laboratory for Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ³Bioceros, Utrecht, Netherlands, ⁴Div. of Clinical Immunology & Rheumatology, Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, ⁵Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁶Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands
Background/Purpose: Immune regulation is necessary for limiting excessive immune responses and for preventing autoimmune diseases. Nuclear factor (NF)-κB signalling plays an important role in the…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].